Maven Securities’s Generation Bio GBIO Stock Holding History

Maven Securities’s Portfolio GBIO Stock Details GBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5,000	Closed	-$1.05M	–	661
2020 Q2	$1.05M	Buy	+5,000	New	+$1.11M	0.07%	202

Other funds holding GBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Maven Securities's GBIO Position: Q3 2020 in Review

Maven Securities sold out of Generation Bio (GBIO) in Q3 2020, closing a stake of 5,000 shares — an estimated $1.05M sold.

Maven Securities first reported a position in GBIO in Q2 2020 and held it in 1 quarter. The position peaked at $1.05M in Q2 2020. 53 funds tracked by Wall St. Rank hold GBIO as of Q3 2020.

Maven Securities reported no remaining Generation Bio position as of Q3 2020 after selling out during the quarter.
Maven Securities sold 5,000 Generation Bio shares in Q3 2020, an estimated $1.05M.
Maven Securities first reported a position in Generation Bio in Q2 2020 and held it in 1 quarter.
Maven Securities's Generation Bio position peaked at $1.05M in Q2 2020.
53 funds tracked by Wall St. Rank held Generation Bio as of Q3 2020.

Based on Maven Securities's 13F filing for Q3 2020, filed 13 Nov 2020.